MARKET

CRDL

CRDL

Cardiol Therapeu
NASDAQ
1.710
-0.020
-1.16%
After Hours: 1.700 -0.01 -0.58% 19:30 09/25 EDT
OPEN
1.750
PREV CLOSE
1.730
HIGH
1.750
LOW
1.670
VOLUME
1.01M
TURNOVER
--
52 WEEK HIGH
2.340
52 WEEK LOW
0.8800
MARKET CAP
206.33M
P/E (TTM)
-7.0720
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), Tango Therapeutics (TNGX) and Cardiol Therapeutics (CRDL)
TipRanks · 3d ago
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
Benzinga · 4d ago
Cardiol Therapeutics Expands Phase III MAVERIC Trial After Early Enrollment Milestone
TipRanks · 4d ago
Cardiol Therapeutics achieves enrollment target for Phase III MAVERIC trial
TipRanks · 4d ago
Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis
Benzinga · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiol Therapeutics (CRDL), Tyra Bioscience (TYRA) and Alibaba Health Information Technology (OtherALBHF)
TipRanks · 5d ago
Weekly Report: what happened at CRDL last week (0914-0918)?
Weekly Report · 6d ago
Cardiol Therapeutics raises over US$7M through warrant exercises
Seeking Alpha · 09/16 12:00
More
About CRDL
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

Webull offers Cardiol Therapeutics Inc stock information, including NASDAQ: CRDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDL stock methods without spending real money on the virtual paper trading platform.